Dipharma builds cGMP manufacturing suite at US subsidiary24 Feb 2020
Italy’s Dipharma Francis has completed construction of a new cGMP manufacturing suite at its US subsidiary, Kalexsyn, strengthening its service offering and ensuring continuity across the product lifecycle from preclinical to commercialisation , the contract research and development organization announced Monday.
The suite comprises a quality control laboratory --designed and equipped according to latest pharmaceutical quality standards with full CFR21 compliance for data integrity management—and a kilo lab, Dipharma said.
“The new suite marks the achievement of a key milestone within the Exclusive Synthesis growth strategy and reinforces the company’s value proposition to provide reliable innovative solutions to customers: Dipharma Group is now able to cover the whole pharmaceutical chemistry services spectrum, from discovery to marketed drugs,” said Jorge Nogueira, CEO of Dipharma Francis.
He added that with the addition of the new kilo lab, Dipharma has implemented cGMP capability at Kalexsyn, enhancing its range of exclusive services from contract research organisation to CDMO.
With an engineering batch already scheduled for production, Dipharma said it is currently assembling all documents required by the US Food and Drug Administration for Drug Establishment Registration.
Dipharma, which also manufactures active pharmaceutical ingredients, has offices in Italy, the US and China. It bought the then CRO Kalexsyn in 2018.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation